Maxim Group analyst Naz Rahman maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report) yesterday and set a price target of $4.00. The company’s shares opened today at $0.84.
According to TipRanks, Rahman is an analyst with an average return of -9.6% and a 33.57% success rate. Rahman covers the Healthcare sector, focusing on stocks such as PainReform, Vertex Pharmaceuticals, and Viking Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Virpax Pharmaceuticals with a $4.00 average price target.
See the top stocks recommended by analysts >>
VRPX market cap is currently $10.54M and has a P/E ratio of -0.58.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
Read More on VRPX:
